• Login
Thursday, March 5, 2026
Geneva Times
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
    • Article
    • Tamil
No Result
View All Result
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
    • Article
    • Tamil
No Result
View All Result
Geneva Times
No Result
View All Result
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
Home Business

Alembic Pharma Q3 Review – Dolat Capital Maintains ‘Reduce’ On The Stock, Revises Target Price — Here’s Why

GenevaTimes by GenevaTimes
February 4, 2025
in Business
Reading Time: 1 min read
0
Alembic Pharma Q3 Review – Dolat Capital Maintains ‘Reduce’ On The Stock, Revises Target Price — Here’s Why
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter



With limited upside, the brokerage maintains ‘Reduce’ rating with revised target price of Rs 1,004 at 22 times FY27E P/E.

Read More

Previous Post

Trump agrees to pause tariffs on Canada and Mexico but not on China

 Next Post

Ein Riss geht durch die Fraktion – POLITICO
Next Post
Ein Riss geht durch die Fraktion – POLITICO

Ein Riss geht durch die Fraktion – POLITICO

Leave a Reply

Your email address will not be published. Required fields are marked *

ADVERTISEMENT
Facebook Twitter Instagram Youtube LinkedIn

Explore the Geneva Times

  • About us
  • Contact us

Contact us:

editor@thegenevatimes.ch

Visit us

© 2023 -2024 Geneva Times| Desgined & Developed by Immanuel Kolwin

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Editorial
  • Switzerland
  • Europe
  • International
  • UN
  • Business
  • Sports
  • More
    • Article
    • Tamil

© 2023 -2024 Geneva Times| Desgined & Developed by Immanuel Kolwin